Breckenridge Pharmaceutical, Inc. recalls Duloxetine Delayed-Release Capsules
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
- Products
-
- Duloxetine Delayed-Release Capsules
- Where it was sold
-
Nationwide
Nationwide
- Units affected
- 14,749 bottles.
- About this recall
- Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 1000-count bottles, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-747-10